keyword
https://read.qxmd.com/read/37451968/euglycemic-diabetic-ketoacidosis-associated-with-st-segment-elevation-myocardial-infarction-following-sglt-2-inhibitor-therapy
#21
Nart Zafer Baytuğan, Aziz İnan Çelik, Tahir Bezgin, Metin Çağdaş
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the latest approved class of oral antidiabetic agents that inhibit renal SGLT-2 receptors and increase urinary glucose excretion in the luminal membrane of the proximal tubule. Diabetic ketoacidosis (DKA) is a triad of hyperglycemia, ketosis, and a high anion gap with metabolic acidosis. We present the case of 61 years-old men with severe euglycemic DKA (EDKA) complicated ST-segment elevation myocardial infarction following SGLT-2 inhibitor therapy for type 2 diabetes mellitus...
September 2023: American Journal of Emergency Medicine
https://read.qxmd.com/read/37393731/evaluating-the-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-a-nationwide-veterans-health-administration-observational-cohort-study
#22
JOURNAL ARTICLE
Tanvi Patil, Morgan Cook, Jesse Hobson, Alamdeep Kaur, Aliza Lee
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are indicated in patients with or without type 2 diabetes mellitus atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure. Postmarket surveillance data have identified many safety signals which warrants further investigation. We aimed to compare the safety of SGLT-2i and glucagon-like peptide-1 receptor agonists (GLP-1RA). Using the Veterans Health Administration nationwide database, patients with type 2 diabetes mellitus who were newly initiated on a SGLT-2i or GLP-1RA between April 1, 2013 and September 1, 2020 were identified...
August 15, 2023: American Journal of Cardiology
https://read.qxmd.com/read/37332887/assessing-adverse-drug-reaction-reports-for-antidiabetic-medications-approved-by-the-food-and-drug-administration-between-2012-and-2017-a-pharmacovigilance-study
#23
JOURNAL ARTICLE
Britney A Stottlemyer, Michael C McDermott, Mackenzie R Minogue, Matthew P Gray, Richard D Boyce, Sandra L Kane-Gill
OBJECTIVE: Between 2012 and 2017, the U.S. Food and Drug Administration (FDA) approved 10 antidiabetic indicated therapies. Due to the limited literature on voluntarily reported safety outcomes for recently approved antidiabetic drugs, this study investigated adverse drug reactions (ADRs) reported in the FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: A disproportionality analysis of spontaneously reported ADRs was conducted. FAERS reports from January 1, 2012 to March 31, 2022 were compiled, allowing a 5-year buffer following drug approval in 2017...
2023: Therapeutic Advances in Drug Safety
https://read.qxmd.com/read/37313125/euglycemic-diabetic-ketoacidosis-caused-by-empagliflozin-complicated-by-failure-to-thrive-in-a-geriatric-patient
#24
Azeem Rathore, Nidhi Gupta, Cameron Kahn, Dinesh Kadariya
Euglycemic diabetic ketoacidosis (euDKA) is a rare but deadly complication of sodium-glucose cotransport-2 (SGLT-2) inhibitors. Primarily indicated for the treatment of Type 2 Diabetes Mellitus, the incidence of euDKA is expected to rise as SGLT-2 inhibitors become a mainstay therapy for diabetics with heart failure. Diagnosis of euDKA can be difficult given the presence of normoglycemia and is especially challenging among geriatric patients that are complicated by additional comorbidities. We present a case of an elderly male with multiple comorbidities who presented for dehydration and altered mentation from a nursing home facility...
2023: Archive of clinical cases
https://read.qxmd.com/read/37182087/sodium-glucose-cotransporter-2-inhibitors-a-scoping-review-of-the-positive-implications-on-cardiovascular-and-renal-health-and-dynamics-for-clinical-practice
#25
REVIEW
Saliha Erdem, Anoop Titus, Dhruvil Patel, Neel N Patel, Yasar Sattar, James Glazier, M Chadi Alraies
Cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been demonstrated in patients with type 2 diabetes in multiple trials. We aim to provide a comprehensive review of the role of SGLT2i in cardiovascular disease. Reducing blood glucose to provide more effective vascular function, lowering the circulating volume, reducing cardiac stress, and preventing pathological cardiac re-modeling and function are the mechanisms implicated in the beneficial cardiovascular effects of SGLT2 inhibitors...
April 2023: Curēus
https://read.qxmd.com/read/37153973/practical-considerations-for-the-use-of-sglt-2-inhibitors-in-the-asia-pacific-countries-an-expert-consensus-statement
#26
REVIEW
Adrian Liew, Aida Lydia, Bien J Matawaran, Paweena Susantitaphong, Huong Thi Bich Tran, Lee Ling Lim
Recent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in reducing the risks of cardiovascular and renal events in both patients with and without type 2 diabetes mellitus. Consequently, many international guidelines have begun advocating for the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply a glucose-lowering agent. However, despite the consistent clinical benefits and available strong guideline recommendations, the utilization of SGLT-2 inhibitors have been unexpectedly low in many countries, a trend which is much more noticeable in low resource settings...
May 8, 2023: Nephrology
https://read.qxmd.com/read/36969130/fournier-s-gangrene-and-diabetic-ketoacidosis-with-lower-than-anticipated-glucose-levels-associated-with-sglt-2-inhibitor-a-double-trouble
#27
Sonali Vadi, Attar Ismail, Dheeraj Kapoor
Empagliflozin has a demonstrated cardiovascular benefit. It is co-prescribed as a glucose-lowering medication in patients with type II diabetes mellitus. Herein, we discuss dual-emergency side-effects, Fournier's gangrene (FG) and diabetic ketoacidosis with lower-than-anticipated glucose levels in a patient on Empagliflozin, a sodium-glucose transport protein 2 inhibitor (SGLT-2i). The pathophysiologic mechanism of FG in correlation with SGLT-2i is not yet elucidated. SGLT-2i increase predisposition to genital mycotic and urinary infections, a mechanism favouring FG...
2023: Medical Journal, Armed Forces India
https://read.qxmd.com/read/36819400/empagliflozin-associated-euglycemic-diabetic-ketoacidosis-in-a-patient-with-type-2-diabetes-mellitus
#28
Sukhjinder Chauhan, AndreyI Manov, Gundip S Dhillon, Pinak Shah
Euglycemic diabetic ketoacidosis (euDKA) is an uncommon condition, which is characterized by an elevated anion gap metabolic acidosis with ketonemia/ketonuria, in the presence of normal blood glucose levels. Common risk factors for the development of this condition include pregnancy, prolonged fasting, acute pancreatitis, and bariatric surgery. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been identified as a rare cause of euDKA. A recent literature review on PubMed found only 86 case reports of euDKA secondary to SGLT inhibitors published in the medical literature up to December 2022...
January 2023: Curēus
https://read.qxmd.com/read/36689144/euglycemic-diabetic-ketoacidosis-caused-by-alcoholic-pancreatitis-and-starvation-ketosis
#29
JOURNAL ARTICLE
Hye Jeong Han, Allison E Cole, Ashish Verma
Starvation ketosis and pancreatitis are uncommon and underrecognized etiologies of euglycemic diabetic ketoacidosis (DKA). Euglycemic DKA is associated commonly with pregnancy, use of insulin en route to the hospital, and use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A 58-year-old male with past medical history of type II diabetes mellitus and alcoholism presented with chief complaint of nausea, vomiting, and poor oral intake for several weeks. Despite extensive history of diabetes and no recent SGLT-2 inhibitor use, his labs were consistent with euglycemic DKA...
April 2023: Journal of General Internal Medicine
https://read.qxmd.com/read/36580199/safety-of-sodium-glucose-cotransporter-2-inhibitors-sglt2i-during-the-month-of-ramadan-in-patients-with-type-2-diabetes-mellitus-in-pakistani-population-an-observational-study-from-a-tertiary-care-center-in-karachi
#30
JOURNAL ARTICLE
Aisha Sheikh, Bhagwan Das, Saadia Sattar, Najmul Islam
BACKGROUND AND AIMS: Primary aim was to assess the safety of SGLT2-i in patients with Type 2 Diabetes Mellitus (T2D) in a real-life scenario during Ramadan by finding the frequency and severity of hypoglycemic/hyperglycemic events, dehydration, and Diabetic ketoacidosis (DKA). Secondary aim was to assess changes in glycated hemoglobin (HbA1c), weight and creatinine levels. METHODS: This prospective, observational, controlled cohort study was conducted at Aga Khan University Hospital, Karachi, Pakistan from March 15 to June 30, 2021...
December 29, 2022: Endocrine
https://read.qxmd.com/read/36576563/sglt-2-inhibitors-and-euglycemic-diabetic-ketoacidosis-diabetic-ketoacidosis-in-faers-a-pharmacovigilance-assessment
#31
JOURNAL ARTICLE
Zhichao He, Kakei Lam, Wenxia Zhao, Shan Yang, Yu Li, Jiayao Mo, Siyuan Gao, Dan Liang, Kaifeng Qiu, Min Huang, Junyan Wu
AIMS: To investigate the main feature and the association between euglycemic diabetic ketoacidosis (euDKA) /diabetic ketoacidosis (DKA) and sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) from the FDA adverse event reporting system (FAERS). METHODS: Cases of SGLT-2i-associated with euDKA/DKA were extracted from the FAERS database and compared with the reports for other hypoglycemia agents (ATC10 class). Disproportionality analyses used the reporting odds ratio (ROR) and information components (IC)...
December 28, 2022: Acta Diabetologica
https://read.qxmd.com/read/36407033/a-possible-novel-effect-for-dapagliflozin-in-the-management-of-subcutaneous-insulin-resistance-syndrome-a-report-of-two-cases
#32
Nabil W G Sweis, Ahmad Albanna, Rama Alhasoun, Ayman Zayed
INTRODUCTION: Subcutaneous insulin resistance syndrome (SIRS) is a rare condition in which patients poorly respond to subcutaneous (SC) insulin but maintain a normal response to intravenous (IV) insulin. The underlying pathophysiology remains elusive. Several treatment regimens have been tested for the management of SIRS, none of which included a sodium-glucose cotransporter-2 inhibitor (SGLT-2). CASE PRESENTATION: Two cases of type 1 diabetes initially achieved adequate glycemic control with subcutaneous insulin...
July 2022: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/36404821/safety-and-effectiveness-of-newer-antidiabetic-medications-during-ramadan-fasting-and-safety-of-ramadan-fasting-after-bariatric-surgery
#33
REVIEW
Musaab Ahmed, Safaa Badi, Ala Elidrisi, Nazik Elmalaika Husain, Sueziani Binte Zainudin, Arshad Mahmood, Nuha Eljaili Abubaker, Abdullah S Alghamdi, Mohamed H Ahmed
BACKGROUND: Fasting during Ramadan is mandatory for all adult healthy Muslims. International studies found that most Muslims with diabetes mellitus fast during Ramadan. The main risk factors are hypoglycemia, Hyperglycemia, diabetic ketoacidosis, and dehydration during fasting. Therefore, stratification of the risks for severe acute diabetes complications needs to be considered for each individual and strategies personalized to advert these complications. The advent of new diabetes medications which are effective yet with a better safety profile and monitoring of blood glucose levels during the day are important to reduce the risk of untoward effects of hypoglycemia and hyperglycemia during Ramadan fasting...
December 2022: Journal of Diabetes and Metabolic Disorders
https://read.qxmd.com/read/36381906/a-case-of-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis
#34
Shiavax J Rao, Kaushik Kumar, Nahar Saleh
While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA.
October 2022: Curēus
https://read.qxmd.com/read/36372219/an-unusual-cause-of-acidosis-in-a-man-with-a-clostridium-difficile-colitis
#35
JOURNAL ARTICLE
P Oriot, E Aldersons, P-A Rogghe
No abstract text is available yet for this article.
November 10, 2022: Gastroenterology
https://read.qxmd.com/read/36371968/a-series-of-diabetic-ketoacidosis-associated-with-the-use-of-sodium-glucose-co-transporter-2-inhibitors-in-secondary-care
#36
JOURNAL ARTICLE
Sofia Taverner, Cindy Eng, Rebecca Watson, Siba George, Amanda Edwards, David M Williams, Jeffrey W Stephens
BACKGROUND AND AIMS: Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are associated with diabetic ketoacidosis (DKA), however limited case series are published. METHODS: We evaluated the characteristics of patients admitted with SGLT-2i associated DKA. RESULTS: Over 4 months, 22 patients were identified; 45.5% of DKA was not associated with concurrent illness. CONCLUSION: DKA is not uncommonly associated with SGLT2i with no clear patient factors associated with severity...
November 2, 2022: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/36320965/a-literature-review-of-the-therapeutic-perspectives-of-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis
#37
REVIEW
Khyati Patel, Arun Nair
Euglycemic diabetic ketoacidosis (DKA), a side effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors, is a triad of high metabolic anion gap acidosis, raised serum and urine ketones, and serum glucose <250 mg/dl. SGLT2 inhibitors cause a carbohydrate deficit by glucosuria, which leads to an increased glucagon/insulin ratio, the metabolic shift from glucose to lipid utilization causing ketogenesis, and hence euglycemic DKA. Additional factors like the ketogenic diet, illness, surgery, and pregnancy contribute to precipitating these episodes...
September 2022: Curēus
https://read.qxmd.com/read/36294370/physicians-considerations-and-practice-recommendations-regarding-the-use-of-sodium-glucose-cotransporter-2-inhibitors
#38
REVIEW
Serge A Jabbour, Nasrien E Ibrahim, Christos P Argyropoulos
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), although initially developed as glucose-lowering drugs, provide significant beneficial effects on cardiorenal outcomes, including heart failure, regardless of type 2 diabetes status. Integration of SGLT-2is into clinical practice requires practical guidance for physicians about their use. To overcome physicians' clinical inertia for SGLT-2i use, including addressing safety, potentially a barrier to their use, a roundtable discussion with physicians from three specialties (cardiology, endocrinology, and nephrology) was conducted...
October 13, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/36216492/sglt2-inhibitors-and-safety-in-older-patients
#39
REVIEW
Rena Pollack, Avivit Cahn
SGLT2 inhibitors (SGLT2i) are effective in the management of diabetes and in reducing adverse cardiovascular and renal outcomes. Randomized clinical trials demonstrated safety and tolerability in older adults. Adverse effects associated with SGLT2i are impacted by patient frailty, comorbidities, and concomitant medication use and, therefore, must be thoroughly evaluated before initiating treatment. The risk of volume depletion, hypoglycemia, genital infections, and diabetic ketoacidosis can be minimized by appropriate patient selection, patient education, and early symptom recognition...
October 2022: Heart Failure Clinics
https://read.qxmd.com/read/36113958/sglt-2-inhibitor-associated-euglycaemic-diabetic-ketoacidosis-in-an-orthopaedic-trauma-patient
#40
JOURNAL ARTICLE
Duncan Taylor Ritchie, James Dixon
Euglycaemic diabetic ketoacidosis is a serious but rare adverse effect of treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A man in his 60s with type 2 diabetes mellitus underwent total hip replacement for an intracapsular neck of femur fracture. His SGLT-2 inhibitor was continued perioperatively and blood glucose levels were normal throughout the admission. A diagnosis of severe euglycaemic diabetic ketoacidosis was made in the operating theatre which required treatment in a critical care unit...
September 16, 2022: BMJ Case Reports
keyword
keyword
72847
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.